ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1775

Predicting Relapse in Patients with Granulomatosis with Polyangiitis – the Potential Use of Monitoring in Vitro ANCA Production

Judith Land1, Wayel H. Abdulahad1, Coen A. Stegeman2, Peter Heeringa3 and Abraham Rutgers1, 1Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 2Nephrology, University Medical Center Groningen, Groningen, Netherlands, 3Pathology and Medical Biology, University Medical Center Groningen, Groningen, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: ANCA, B cells and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Patients with granulomatosis with polyangiitis (GPA) suffer from frequent disease relapses, with up to 50% of patients relapsing within 5 years. Several risk factors for relapse have been described, such as persistent ANCA titers and Staphylococcus aureus nasal carriage. However, no method to predict a relapse in individual patients is currently known. Changes in measures that reflect the pathogenic process in the patient may be useful to improve relapse prediction in these patients.

Methods

Forty-nine patients with GPA were monitored for a period of 8-16 months, with 3-7 sampling moments for each patient. At each time point peripheral blood mononuclear cells were cultured in presence of CpG-oligodeoxynucleotides, B-cell activating factor and interleukin-21 for 12 days. Subsequently supernatants were analysed for PR3-ANCA by Phadia EliA, results being expressed in response units (RU), and production of total IgG was assessed by ELISA. Moreover, ANCA titers were determined by immunefluorescence. B cell phenotypes were analysed by using flow cytometry on whole blood stained for CD19, CD24, CD27 and CD38. With these markers percentages and total numbers of B cells were determined, and naive, transitional, memory and regulatory B cells were distinguished. Median values from the last measured time point before relapse were compared to non-relapsing patients. For non-relapsing patients the average value of all time points measured was used. All patients were also scored based on their inclusion sample and subsequently analyzed for differences in disease-free survival.

Results

During follow-up 12 patients relapsed. Patients that relapsed showed higher median values of in vitro PR3-ANCA (9.1 RU vs 2.2 RU) as well as higher ANCA titers compared to the non-relapsing patients. The higher levels of PR3-ANCA IgG were not a reflection of higher total IgG production, levels of IgG were in fact decreased in patients before relapse. Three patients relapsed directly after the inclusion sample, two of which showed >15 RU of in vitro PR3-ANCA. Of the remaining nine patients, six were positive for PR3-ANCA, and also showed an increase in this measure prior to relapse. Patients that had >2 RU of in vitro PR3-ANCA at inclusion showed lower disease-free survival, while no such difference was observed for ANCA titer or total IgG. The median percentages of memory and regulatory B cells, both CD24hiCD38hi and CD24hiCD27+ , were lower in patients prior to relapse. However, no differences in disease-free survival were observed when patients were divided based on percentage at inclusion. When analyzing the absolute numbers of B cell subsets patients with low numbers of CD27+ memory B cells at inclusion were shown to be more prone to relapse.  

Conclusion

This study shows a few promising factors to assist in the prediction of relapse in GPA patients, most notably in vitro ANCA production. Finding a better predictive factor for relapse in GPA would allow for timely intervention and possibly prevention of relapse in patients. Currently 80 PR3-ANCA positive GPA patients are being monitored with this method to strengthen these data.


Disclosure:

J. Land,
None;

W. H. Abdulahad,
None;

C. A. Stegeman,
None;

P. Heeringa,
None;

A. Rutgers,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predicting-relapse-in-patients-with-granulomatosis-with-polyangiitis-the-potential-use-of-monitoring-in-vitro-anca-production/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology